Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches

Table 1 Efficacy outcomes with antiangiogenic agents in recurrent glioblastoma.

Reference, (n^a)	Treatment regimen	Response rate (%)^b			Progression-free survival
		CR	PR	SD	Median	At 6 months (%)
Bevacizumab
Vredenburgh [28], (n = 23 of 32)^d	BV + irinotecan	4	57	35	20 weeks	30
Vredenburgh [29], (N = 35)	BV + irinotecan	57		N/A	24 weeks	46
Narayana [33], (n = 37 of 61)^e	BV + irinotecan or carboplatin	13	60	21	5 months	N/A
Friedman [31], Cloughesy [32], (N = 167)	BV alone (n = 85) BV + irinotecan (n = 82)	28 38		N/A N/A	4.2 months 5.6 months	43 50
Reardon [38], (n = 27 of 59)^d	BV + etoposide	4	19	70	18 weeks	44
Kreisl [49], (N = 48)	BV → BV + irinotecan	71 (Levin criteria); 35 (MacDonald criteria)		N/A	16 weeks	29
Gutin [92], (n = 20 of 25)^d	BV + hypofractionated stereotactic irradiation	50		N/A	7.3 months	65
Aflibercept
De Groot [53], (n = 32 of 48)^d	Aflibercept alone	0	30	52	N/A	N/A
Cediranib
Batchelor [112], (N = 31)	Cediranib alone	57 (volumetric criteria); 27 (MacDonald criteria)		N/A	117 days	26
Cilengitide
Reardon [50] (N = 81)	Cilengitide alone (2000 mg/d [n = 40] or 500 mg/d [n = 41])	0	9	N/A	2000 mg/d, 8.1 weeks^c 500 mg/d, 7.9 weeks^c	2000 mg/d, 15 500 mg/d, 10
CT-322
Schiff [113], (n = 51)	CT-322 alone (n = 33) CT-322 + irinotecan (n = 18)	1 (3) 0	1 (3) 0	N/A N/A	N/A N/A	23 48
XL184
Wen [54], (n = 105)	XL184 175 mg qd XL 184 125 mg qd	AAT-naive (n = 34), 21 AAT-pretreated (n = 12), 8 AAT-naive (n = 37), 30 AAT-pretreated (n = 22), 0		N/A	AAT-naive, 16 weeks AAT-naive, 16 weeks AAT-pretreated, 7.9 weeks	AAT-naive, 10 AAT-naive, 25 AAT-pretreated, 0

Abbreviations: AAT = antiangiogenic therapy; BV = bevacizumab; CR = complete response; N/A = not available; PR = partial response; RT = radiotherapy; SD = stable disease.
^aNumber of patients with glioblastoma, where available.
^bIn evaluable patients.
^cTime to progression.
^dEfficacy outcomes are reported for patients with glioblastoma only.
^eEfficacy outcomes are reported for all patients.

ISSN: 1748-717X